Key Takeaways
- The only published human trial (Teichman et al., 2006, n=64) found injection-site reactions, flushing, and headache as the most common adverse events, all mild and transient.
- CJC-1295 with DAC has a half-life of roughly 6 to 8 days, meaning any side effect from a dose persists far longer than with shorter-acting GHRH analogs.
- Chronically elevated IGF-1 carries a plausible, mechanism-supported cancer risk that no CJC-1295 trial has been long enough or large enough to detect or rule out.
- No head-to-head safety trial compares CJC-1295 to sermorelin or tesamorelin; sermorelin has the longest clinical safety record among GHRH analogs in humans.
- Most products sold as CJC-1295 are research-grade, not pharmaceutical-grade, meaning purity, sterility, and actual peptide content are not guaranteed by any regulatory body.
Direct Answer: What Are the CJC-1295 Side Effects?
CJC-1295 side effects documented in human trials are mostly mild: injection-site pain, redness, flushing, headache, and transient dizziness. Serious adverse events have not been reported in published data, but trial duration was short (up to 28 days) and sample sizes were small. Longer-term risks from sustained IGF-1 elevation are mechanistically plausible but unstudied in this compound specifically.
Table of Contents
- What is CJC-1295 and how does it cause side effects?
- Evidence ledger: each side effect graded
- Mechanism with numbers: why the DAC modification changes the risk profile
- What most pages get wrong about CJC-1295 side effects
- CJC-1295 long-term side effects: what we do and do not know
- Does elevated IGF-1 raise cancer risk?
- Honest head-to-head: CJC-1295 vs. sermorelin vs. tesamorelin
- Operational guide: reading a COA, recognizing degradation, dosing math
- Chemistry behind the rules: why storage and mixing matter
- FAQ
- Sources
What Is CJC-1295 and How Does It Cause Side Effects?
CJC-1295 is a 30-amino-acid synthetic analog of growth-hormone-releasing hormone (GHRH). The native GHRH peptide is cleaved and inactivated by dipeptidyl peptidase IV (DPP-IV) within minutes. CJC-1295 was engineered with a maleimidoproprionic acid (MPA) side-chain that reacts with the cysteine-34 position of circulating albumin, forming a covalent bond and dramatically extending its plasma half-life.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Once bound to albumin, CJC-1295 continues to activate GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary. This drives increased GH secretion, and the liver responds by producing more insulin-like growth factor 1 (IGF-1). Every downstream side effect traces back to one of two things: elevated GH, elevated IGF-1, or the injection delivery itself.
Evidence Ledger: Each Side Effect Graded
| Side Effect | Best Evidence Type | Direction | Confidence | Notes |
|---|---|---|---|---|
| Injection-site pain, redness, swelling | Human RCT (Teichman 2006) | Occurs in a subset of users | High | Mild, self-limiting in all reported cases |
| Flushing / warmth | Human RCT (Teichman 2006) | Reported at higher doses | High | Transient, dose-dependent |
| Headache | Human RCT (Teichman 2006) | Mild, transient | Moderate | Not systematically quantified by severity |
| Dizziness | Human RCT (Teichman 2006) | Mild, transient | Moderate | Likely related to acute GH surge |
| Water retention / peripheral edema | Mechanism (GH excess biology); no CJC-specific trial | Plausible at supraphysiological doses | Low (for CJC-1295 specifically) | Well established for exogenous GH and acromegaly |
| Carpal tunnel syndrome | Mechanism; documented for exogenous GH therapy | Plausible with chronic use | Low | No CJC-1295 case reports in published literature |
| Joint and muscle pain (myalgia/arthralgia) | Mechanism; documented for exogenous GH | Plausible | Low | More likely with very high IGF-1 |
| IGF-1 elevation and cancer risk | Epidemiology (IGF-1 and cancer); mechanism; no CJC causal data | Plausible concern | Very low (causal for CJC), Moderate (mechanistic plausibility) | See dedicated section below |
| HPA/GH axis suppression with chronic use | Animal studies; GHRH analog theory; no human CJC data | Possible with prolonged use | Very low | Unstudied at typical protocol durations |
| Glucose/insulin dysregulation | Mechanism (GH is insulin-antagonistic); no CJC trial data | Possible at high doses | Very low | Clinically relevant in pre-diabetic individuals |
Mechanism with Numbers: Why the DAC Modification Changes the Risk Profile
Native GHRH(1-44) has a plasma half-life of roughly 7 minutes due to DPP-IV cleavage. Sermorelin (GHRH 1-29) fares slightly better but still clears in roughly 10 to 20 minutes. CJC-1295 without DAC (also called modified GRF 1-29) shares a similar short half-life. CJC-1295 with DAC, by contrast, binds albumin covalently and achieves a half-life of approximately 6 to 8 days, as measured in the Teichman 2006 dose-escalation study across doses of 30 to 120 mcg/kg.
In that same trial, a single injection raised mean GH area-under-the-curve significantly above baseline for up to 6 days, and mean IGF-1 levels increased by 35 to 55 percent above baseline and remained elevated for 9 to 11 days at the higher doses tested. This is the mechanistic crux: with a long half-life compound, a dosing error, an unexpected sensitivity, or a decision to stop using the compound mid-protocol does not correct itself overnight. You are committed to several days of elevated GH and IGF-1 regardless of what you do after injection.
What this mechanism does NOT prove: elevated IGF-1 percentages seen in a 28-day trial do not tell you what happens to IGF-1 at month 6 of weekly dosing, whether somatostatin counter-regulation normalizes things, or what the tissue-level consequences are in any specific organ. The numbers describe what happens in the bloodstream over weeks, not what happens in breast epithelium, prostate stroma, or colon mucosa over years.
What Most Pages Get Wrong About CJC-1295 Side Effects
The overwhelming majority of CJC-1295 content on the internet either (a) lists speculative side effects as if they are observed facts, or (b) dismisses real mechanistic concerns as negligible. Three specific things almost no page discusses honestly:
1. The purity problem is more dangerous than the pharmacology. CJC-1295 is not FDA-approved and is not manufactured under pharmaceutical GMP for human use in most commercial contexts. Research-grade peptides can contain residual solvents, bacterial endotoxins (lipopolysaccharide), and incorrectly folded or truncated peptide sequences. Endotoxin contamination from gram-negative bacteria during synthesis causes fever, rigors, and in severe cases septic shock, none of which is a pharmacological side effect of the peptide itself. A page that only lists "flushing" and "headache" without mentioning injection-site infection, sterile abscess, or endotoxin reaction is giving a materially incomplete risk picture.
2. "No serious adverse events in trials" is not the same as "safe." The Teichman 2006 trial enrolled 64 subjects and ran for 28 days. This sample size and duration have essentially no statistical power to detect a rare event or a slow-developing harm. The absence of evidence from a small short trial is genuinely not evidence of absence for chronic or uncommon risks.
3. The DAC version is not interchangeable with the non-DAC version. Many vendors and users conflate CJC-1295 (with DAC) and modified GRF 1-29 (without DAC). They differ not just in half-life but in their GH secretion pattern: DAC produces a prolonged blunted elevation, while the non-DAC version more closely mimics natural GHRH pulsatility. The risk profiles are therefore different, and conflating them in a side-effects discussion is inaccurate.
CJC-1295 Long-Term Side Effects: What We Do and Do Not Know
The honest answer is that long-term human safety data for CJC-1295 specifically does not exist. The compound never completed clinical development for any indication. There is no published trial lasting beyond 28 days in humans. Everything said about long-term CJC-1295 side effects is extrapolated from one of three imperfect analogies:
Exogenous GH therapy: Long-term GH replacement in adults with diagnosed GH deficiency is associated with edema, arthralgia, carpal tunnel syndrome, glucose intolerance, and a debated increase in cancer risk. These are dose-dependent effects and generally emerge at doses that produce supraphysiological IGF-1. They are the best available proxy for what could happen with chronic GH secretagogue use at high doses.
Acromegaly biology: Acromegaly (endogenous GH excess) causes well-documented cardiovascular, metabolic, and neoplastic complications. This represents the extreme end of what GH excess does over years, and is not a direct analog for peptide use, but it describes the direction of risk.
GHRH analog research: Tesamorelin, a GHRH analog approved by the FDA for HIV-associated lipodystrophy, has multi-year safety data and is the closest approved analog. Its long-term profile includes glucose elevation and IGF-1 elevation; it also carries language about theoretical neoplasm risk in its prescribing information.
Does Elevated IGF-1 Raise Cancer Risk?
This question deserves a direct answer rather than evasion. Large prospective cohort studies including data from the European Prospective Investigation into Cancer and Nutrition (EPIC) have found statistically significant associations between higher circulating IGF-1 levels and increased risk of colorectal, premenopausal breast, and prostate cancer. These are associations from observational data, not randomized trials, so causation is not proven. However, the mechanism is credible: IGF-1 activates the PI3K/AKT/mTOR pathway, which drives cell proliferation and suppresses apoptosis in multiple tissue types.
CJC-1295 raises IGF-1. The Teichman trial documented increases of 35 to 55 percent above baseline at the doses studied. Whether those elevations, sustained over months of repeated dosing in a typical protocol, reach or exceed the IGF-1 ranges associated with increased cancer risk in epidemiological studies is unknown because no one has measured it longitudinally in this context.
The honest statement is: there is a plausible mechanism, a supporting epidemiological signal from IGF-1 literature, and a complete absence of long-term cancer incidence data for CJC-1295 specifically. Any risk communication that dismisses this concern entirely is not credible; any that frames it as a certainty is also not credible.
Honest Head-to-Head: CJC-1295 vs. Sermorelin vs. Tesamorelin
| Feature | CJC-1295 (with DAC) | Sermorelin | Tesamorelin |
|---|---|---|---|
| Regulatory status (US) | Not approved; research compound | Not approved (was FDA-approved, discontinued 2008) | FDA-approved (Egrifta, HIV lipodystrophy) |
| Half-life | Roughly 6 to 8 days | Roughly 10 to 20 minutes | Roughly 26 minutes |
| GH secretion pattern | Prolonged, blunted elevation | Pulsatile, close to physiological | Pulsatile, close to physiological |
| Published human safety trials | 1 RCT (Teichman 2006, n=64, 28 days) | Multiple, including pediatric data | Multiple Phase 3 trials, multi-year extension data |
| IGF-1 elevation magnitude | Large (35 to 55% above baseline in Teichman) | Moderate, closer to physiological | Moderate (documented in Falutz 2008 trial) |
| Injection-site reactions | Reported in RCT | Reported clinically | Reported in RCT (most common AE in Falutz) |
| Glucose effects | Plausible, not specifically measured long-term | Low risk at physiological doses | Documented glucose elevation in long-term tesamorelin trials |
| Where CJC-1295 LOSES | Longer AE duration if problem occurs, least human data, no approved indication | Shorter duration limits sustained effect | Cost, prescription requirement, narrow approved indication |
CJC-1295 loses clearly on safety data depth and regulatory oversight. It also loses on the time-to-recovery dimension: if you have an adverse effect from sermorelin, it clears in under an hour. With CJC-1295 DAC, elevated GH persists for nearly a week.
Operational Guide: Reading a COA, Recognizing Degradation, Dosing Math
What a legitimate COA should contain: Peptide sequence confirmation (typically by HPLC and mass spectrometry), purity percentage (research-grade minimum is generally quoted as above 98% by HPLC), endotoxin test result (LAL test, reported in EU/mg), sterility test result, and molecular weight confirmation matching the theoretical value for CJC-1295 (roughly 3647 Da for the DAC form).
What a COA cannot tell you: Whether the vial you received matches the lot that was tested. Third-party testing of finished vials is the only way to verify what you actually have.
Recognizing degradation: Lyophilized CJC-1295 should be a white to off-white dry cake or powder. After reconstitution with bacteriostatic water, the solution should be clear and colorless with no visible particulates. Yellow or brown color, cloudiness, or a particulate suspension signals oxidation, microbial contamination, or decomposition. Do not use such a vial.
Reconstitution math: If a vial contains 2 mg (2000 mcg) of lyophilized CJC-1295 and you add 2 mL of bacteriostatic water, the resulting concentration is 1000 mcg per mL, or 1 mcg per microliter. A dose of 200 mcg would therefore be drawn to 0.2 mL on a standard insulin syringe (the 20-unit mark on a U-100 syringe). Verify your vial quantity, reconstitution volume, and target dose before every preparation.
Storage: Lyophilized peptide is stable when stored dry at 2 to 8 degrees C, away from light. Reconstituted solution should be refrigerated and used within a reasonable window (commonly cited as 28 to 30 days, though formal stability data for this specific compound at typical storage conditions is not publicly available from peer-reviewed sources). Freeze-thaw cycles degrade peptide bonds and should be avoided.
Chemistry Behind the Rules: Why Storage and Mixing Matter
Why not to mix with vitamin C (ascorbic acid) solutions: Ascorbic acid is a reducing agent. Many peptide bonds and particularly methionine-containing sequences are vulnerable to oxidation, and while the reducing environment theoretically protects from oxidation, the acidic pH of ascorbic acid solutions (typically pH 3 to 4) can catalyze hydrolysis of certain peptide bonds, fragmenting the molecule. More practically, bacteriostatic water (pH roughly 5 to 7) is the standard diluent precisely because it is near-neutral and isotonic-compatible.
Why temperature matters: Peptides are held in three-dimensional conformations by hydrogen bonds and van der Waals forces. Heat increases molecular motion and the rate of both hydrolysis (water attacking peptide bonds) and racemization (conversion of L-amino acids to D-amino acids, which are biologically inactive). This is why lyophilization (freeze-drying) is used for storage in the first place, and why reconstituted solution degrades faster at room temperature.
Why the DAC bond is irreversible once degraded: The maleimidoproprionic acid group on CJC-1295 reacts with the free thiol of albumin's Cys34 via a Michael addition, forming a stable thioether bond. Once this bond forms correctly in plasma, the complex is stable. However, if the peptide oxidizes in the vial before injection (maleimide groups can hydrolyze or react with oxygen), the DAC modification becomes non-functional, and you effectively inject a short-acting, possibly inactive fragment. You would not know from visual inspection alone.
FAQ
Sources
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322.
- Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353.
- Key TJ, Appleby PN, Reeves GK, et al; Endogenous Hormones Breast Cancer Collaborative Group. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11(6):530-542.
- Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797.
- Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609.
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
- Egrifta (tesamorelin for injection) US prescribing information. Theratechnologies Inc. 2015 (and subsequent updates). Available via FDA label archive.
- Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf). 2007;67(1):65-70.